Sofosbuvir reference collection


My favourite overview: i-base http://i-base.info/htb/27153

Gilead financial success on sofosbuvir

  • Fastest-selling drug in history
  • Shares steadily rising
  • Made CEO a billionaire in March (2014)

http://www.bloomberg.com/news/2014-03-03/gilead-ceo-becomes-billionaire-on-84-000-hepatitis-drug.html

  • 9 billion estimated in first three quarters
  • New drug – Harvoni. ~95,000 USD

http://online.wsj.com/articles/gilead-gets-u-s-approval-to-sell-new-hepatitis-c-drug-1412963083

(Real and effective) R&D costs

Over the period of sofosbuvir development (2009-2011), Pharmasset reported total R&D expenditure of 172mil, of which 62mil are directly attributable to sofosbuvir. [This means less than 2% of the 11bil cost being recouped by Gilead goes to compensating the R&D investment]
bottom of page 3, http://www.finance.senate.gov/imo/media/doc/Wyden-Grassley%20Document%20Request%20to%20Gilead%207-11-141.pdf

UK

NHS will treat 500 patients
http://www.england.nhs.uk/2014/04/16/hepatitis-c/
there are 216,000 patients with hep C in the UK
http://www.patient.co.uk/doctor/hepatitis-c-pro

UAEM response to gilead licence

http://uaem.org/gileads-hepatitis-c-treatment-license-misses-the-mark-despite-some-increased-competition/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s